The delivery of therapeutic genes to primary brain neoplasms opens new opportunities for treating these frequently fatal tumors. Efcint gene delivery to tissues remains an important obstacle to therapy, and this problem has unique characteristics in brain tumors due to the blood-brain 
unique characteristics in brain tumors due to the blood-brain and blood-tumor barriers. The presence ofendothelial mitogens and vessel proliferation within solid tumors
Iets that genetically modified endothelial cells might efficiently transplant to brain tumors. Rat brain endothelial cells immortalized with the adenovirus ElA gene and further modified to express the -galactosidase reporter were examined for their ability to survive implantation to experimental rat gliomas. Rats received 9L, F98, or C6 glioma cells in combination with endotheflal cells inucranilaly to caudate/putamen or subcutaneously to flank. Implanted endothellal cells were identified by P-galactosidase histohemistry or by polymerase chain reaction in all tumors up to 35 days postimplantation, the latest time examed. Implanted endothelial cells appeared to cooperate in tumor vessel formation and expressed the brain-specific endothelial glucose transporter type 1 as idenfied by immunohi emistry. The proliferation of implanted endothelial cells was supported by their increased number within tumors between postimplantation days 14 and 21 (P = 0.015) and by their expression of the proliferation antigen K167. These finding establish that genetically m ifd endothellal cells can be stably engrafted to growing gl s and suggest that endothelial cell implantation may provide a means of delivering therapeutic genes to brain neoplasms and other solid tumors. In addition, endothelial implantation to brain may be useful for defining mechanisms of brain-specific endothelial differentiation.
Gene therapy is receiving considerable attention as a method for targeting putative therapeutic biological substances directly to brain and brain tumors. The most efficient and least toxic methodologies for delivering functional genetic material to normal and neoplastic tissues within the central nervous system (CNS) are not established and will likely be tailored to specific diseases. Because the blood-brain and bloodtumor barriers limit entry of blood-borne compounds (1), innovative approaches for delivering genetic material to these sites are being explored. Among those presently receiving attention are (i) systemic administration of neurotropic viral vectors (2-4), (ii) direct interstitial administration of nucleic acids (5) , and (iii) transplantation of cells after their genetic modification and characterization ex vivo (6, 7) .
Endothelial cells are a particularly suitable platform for gene therapy (8) (9) (10) . Their location at the parenchymal-blood interface is ideal for delivering transgene products either systemically or locally, and they are easily cultured from diverse tissue sources. Since endothelial cells proliferate in vitro, they accommodate a broad spectrum of vectors and to date have been successfully transduced to express numerous products with therapeutic potential (11) (12) (13) . Various approaches to using endothelial cells as platforms for transgene expression in vivo have been successful, including direct gene transfer in vivo (14, 15) and the seeding of denuded host arteries (16) , limb microvessels (17) , and prosthetic vascular implants with endothelial cells genetically modified in vitro (18) . These approaches hold promise for the systemic delivery oftransgene products but do not specifically address their delivery across the blood-brain barrier.
The endothelial mitogens and prominent vessel proliferation within solid tumors suggested to us that endothelial cells might efficiently be transplanted to brain tumors (19, 20) . This report demonstrates that genetically modified endothelial cells successfully implant, proliferate, and survive for extended periods oftime in three experimental rat gliomas. Our findings establish the potential for using genetically modified endothelial cells as platforms for delivering therapeutic gene products to brain tumors. They also suggest that endothelial transplantation to the CNS may be a useful tool for studying mechanisms of CNS vascularization, endothelial differentiation, and blood-brain barrier formation in brain and brain tumors.
METHODS
Endothelial Cells. Endothelial cells to be used for implantation were isolated from rat brain; after one passage, they were immortalized by transfection with pElA-neo, which contains the adenovirus 2 ElA gene and a neomycinresistance gene. One clone, designated RBE4, has been further characterized; it exhibits contact inhibition and growth factor-and anchorage-dependent proliferation and is labeled with the endothelial-specific markers factor VilIrAg and acetylated low density lipoprotein (21) . RBE4 cells were subsequently exposed to the replication-defective MFG-NB retroviral vector containing a modified lacZ gene (nls-4acZ) (22) , which codes for the Escherichia coli f-galactosidase ((3-gal) fused to a 21-amino-acid nuclear localization sequence (nls) from simian virus 40 (30) . Some sections were immunohistochemically stained for laminin (27) , the nuclear proliferation antigen Ki67 (31) , or the brain-specific endothelial glucose transporter type 1 (Glut-i) (27) after staining with X-Gal. Sections for laminin staining were digested for 15 min at 37°C with 0.2% pepsin in 0.01 M HCO prior to incubation with immunological reagents. Sections were sequentially incubated with 1% normal goat serum and either rabbit anti-laminin (Sigma), rabbit antiGlut-i (kindly provided by Lester Drewes, University of Minnesota, Duluth), or rabbit anti-Ki67 (Dakopatts, Glostrup, Denmark). Sections incubated with anti-laminin and anti-Glut-1 were then incubated with biotinylated goat antirabbit immunoglobulin (Vector Laboratories) and then avidin-biotin complex reagent (Vector Laboratories) followed by 3,3'-diaminobenzidine (0.5 mg/ml; Sigma) in 50 mM Estimates of the total number of RBEZ cells per tumor were derived from the number of RBEZ cells per tumor volume (12-,um section), and estimates of total tumor volume were derived from maximum cross-sectional tumor areas (32) .
PCR. Synthetic oligonucleotides complementary to the DNA sequences located in the nls-acZ gene (5'-CGAC-TCCTGGAGCCCGTCAGTATC-3') and in the vector upstream of the 3' long terminal repeat (5'-GACCACT-GATATCCTGTCTTTAAC-3') were used as primers (22) .
PCR reactions were performed on genomic DNAs isolated from control tumors, experimental tumors, and positive and negative control cell lines. Thirty-five cycles of amplification with Thermus aquaticus (Taq) polymerase (Cetus) were performed at temperatures of 950C for denaturation, 600C for hybridization, and 720C for elongation.
RESULTS
Implantation of Endotelal Cells to Intracra l and Subcutaneous Experimental Gliomas. The immortalized microvascular endothelial cell line from rat brain (33) modified to express the nls-lacZ reporter gene (RBEZ) (22) was used to explore endothelial implantation to 9L, F98, and C6 rat gliomas in vivo. In these studies, glioma cells alone or a mixture of RBEZ cells and glioma cells were implanted to rat caudate/putamen. Because intracranial tumor-related mortality begins during postimplantation week 3, tumors generated by implanting a mixture of 9L glioma cells and RBEZ cells to rat flanks were used to evaluate longer periods of RBEZ cell survival. After staining with the X-Gal chromogenic substrate, blue nuclear (3-gal reaction product was identified in histological sections of all 7-to 12-day postimplantation intracranial tumors and all 14-to 35-day postimplantation subcutaneous tumors as shown in Fig. 1 and Tables 1 and 2 . Interestingly, engrafted endothelial cells were distributed throughout the intracranial tumors, including their finger-like infiltrating margins, but did not appear to migrate into normal tissues unassociated with glioma cells (data not shown). No obvious differences were found in the distribution of RBEZ cells implanted with the different tumor cell types, and no blue X-Gal reaction product was detected in tumors implanted without RBEZ cells (30) . In addition to these histological endpoints, PCR was used to verify the presence of MFG-NB proviral vector DNA in high molecular weight nuclear DNA isolated from tumors implanted with RBEZ cells. Vector-specific DNA sequences were found in DNA isolated from tumors engrafted with RBEZ cells but were not found in control tumors (Fig. 2) .
Location and Differentiation of Implanted Endothelial Cells. We next asked whether implanted endothelial cells associate with the host-derived tumor vessels or reside in tumor parenchyma independent of tumor vessels. Frozen sections from postimplantation day 12 tumors were histochemically stained with X-Gal to detect implanted RBEZ cells and then immunohistochemically stained with either anti-Glut-1 or anti-laminin to detect tumor microvessels (27, 34) . Interestingly, in all tumor types examined numerous engrafted RBEZ cells were found to be associated with microvascular profiles (Fig. 1B) . In linearly associated RBEZ cells were also observed (Fig. 1C) . These findings suggest that RBEZ cells implanted in this fashion have the potential to engraft in an anatomically correct fashion in tumors.
One of the most striking features of brain endothelial cells is their high level expression of the blood-brain barrier glucose transporter Glut-1 (35) . This is consistent with the prominent transendothelial transport of D-glucose, the primary energy substrate of brain. We have previously established that endothelial cells within human and rat intracranial gliomas also express this transporter (27) . Numerous 3-gal-positive cells within tumors were found to stain prominently for Glut-i (Fig. 1D) . Tissue sections obtained from 12-day postimplantation tumors were stained sequentially with X-Gal and antiKi67. Cells expressing both nuclear (-gal and Ki67 antigen were found ( Fig. 1 E and F) . This indicates that a substantial number of implanted RBEZ cells are proliferating outside of Go (31) . (21 days) 5,252,160 ± 611,380 RBEZ cells were implanted concurrent with glioma cells to intracranial or subcutaneous sites in rat as described in Methods. At postimplantation day 12 for intracranial tumors and at the indicated times for subcutaneous tumors, animals were sacrificed by perfusion fixation, and tumor sections were stained with X-Gal to detect surviving RBEZ cells. Tumor cross-sectional areas and the number of RBEZ cells per tumor section were quantitated by image analysis. Total tumor volumes were estimated from cross-sectional areas (32) and used to calculate total tumor RBEZ cells as described in Temporal changes in the number of implanted RBEZ cells were determined as an independent way ofassessing whether RBEZ cells proliferated. Animals bearing RBEZ-containing subcutaneous 9L tumors were sacrificed at postimplantation days 14 and 21, a time interval during which tumor volumes increased about 14-fold. Tumor sections were histochemically stained with X-Gal to detect implanted RBEZ cells. Tumor cross-sectional areas and the numbers of implanted cells per tumor volume (e.g., per 12 ,um tumor section) were quantitated by computer-assisted image analysis. The numbers of RBEZ cells per whole tumor were then calculated by using total tumor volumes estimated from their crosssectional areas (32) . These data indicate that the total number of RBEZ cells per tumor increased about 10-fold over this time interval (Table 2) . These immunofluorescent and morphometric data are consistent with endothelial proliferation within the growing tumors.
DISCUSSION
The delivery of foreign genes to specific tissues remains an important obstacle to gene therapy. One approach is to implant genetically modified "bystander cells" that deliver either transgene protein products (6) or replication-defective viral vectors (37) to neighboring target cells. While it is theoretically possible that nonimmunogenic universal donor cells might someday be available for cell-based gene delivery, autologous implantation is presently optimal to avoid graft rejection. Consequently, primary emphasis has been placed on fibroblasts (6, 38) , myoblasts (7), and endothelial cells (16) (17) (18) , since they are easily obtained from patient biopsy specimens and are readily expandable in culture. Genetically modified fibroblasts and myoblasts produce therapeutic effects after their implantation to experimental animals bearing brain tumors (37) or after brain injury (7) . While genetically modified endothelial cells can be implanted to the vasculature of systemic tissue (16) (17) (18) , to our knowledge, their potential to serve as platforms for delivering genes to either the CNS or to solid tumors has not been previously demonstrated.
Endothelial cells are distinguished from other candidate cell types (e.g., muscle and fibroblast) since (i) they are normal components of brain and brain tumors (20) , (ii) they proliferate in response to the endothelial-specific mitogens found within developing brain and brain tumors, and (iii) their active proliferation is required for tumor growth (39) . These features suggested to us that endothelial cells might be particularly useful for cell-based gene delivery to brain tumors. We show in this report that endothelial cells can be implanted reproducibly to intracranial gliomas and that they maintain reporter gene expression in tumors for prolonged periods. In addition, we found that implanted endothelial cells proliferate, judging from the increased cell numbers during a period of substantial glioma growth and on their expression of the proliferation antigen Ki67 (31) . The proliferation of these contact-inhibited, nontumorigenic endothelial cells (40) is consistent with host-derived vessel proliferation and the presence ofendothelial mitogens within gliomas and demonstrates the potential to maintain large numbers of genetically modified endothelial cells even within growing tumor. This is likely to be an important requirement for delivering adequate amounts of therapeutic transgene products to tumors over extended periods of time. In this study, immortalized brain-derived endothelial cells were implanted simultaneously with glioma cells to brains of non-tumorbearing animals. Since it is unlikely that brain endothelial cells autologous to patients bearing brain tumors will be readily obtainable, it will be important to determine if endothelial cells derived from a peripheral source similarly survive implantation to established tumors.
Messina et al. (17) described the engraftment ofendothelial cells to the rat hindlimb microvasculature. In their report, endothelial cells were delivered to hindlimb microvessels via femoral artery perfusion. We examined the localization of implanted endothelial cells relative to host-derived tumor vessels to determine whether endothelial cells implanted to tumors interstitially have the capacity to organize into vascular forms. Regardless of their localization within tumors, essentially all implanted (-gal-positive cells stained prominently with anti-laminin, consistent with the endothelial phenotype. In addition, numerous cells were associated with small-and medium-sized vessels, suggesting an ability to form vascular structures and to integrate functionally with the host-derived tumor microvasculature. Thus, interstitially implanted endothelial cells appear to undergo vasculogenesis (the coalescence of endothelial cells into vessels) within tumors that are normally vascularized exclusively by angiogenesis (the ingrowth of elongating vessels from surrounding tissues). In light of the blood-tumor barrier, this finding suggests that genetically modified endothelial cells might be a particularly versatile cell-based platform for gene therapy. In addition to the direct delivery of secreted transgene products to tumor cells, implanted endothelial cells engineered to express novel transport systems might enhance the transvascular delivery of blood-borne drugs to tumor (1). More extensive light and electron microscopic studies will be required to quantify the number of implanted cells that associate with tumor vessels and to determine if they intercalate with host-derived endothelial cells at the blood-tumor interface.
Our finding that brain-derived endothelial cells were able to express the brain-specific endothelial glucose transporter Glut-i after implantation is consistent with the expression of Glut-1 by a substantial percentage of host-derived endothelial cells within these tumors (27) The results of this study establish the feasibility of engrafting endothelial cells that have been genetically modified ex vivo to intracranial gliomas. The prospect of endothelial engraftment to the blood-brain interface suggests that these cells might be particularly sensitive to blood-borne regulators of transgene expression and that they might also be used for selective modification of blood-brain barrier function. Additional studies will be required to determine if endothelial implantation can be used to deliver therapeutically effective genes to brain neoplasms and other selected sites with the CNS.
